The glucagon-like peptide-1 receptor (GLP-1R) market experienced significant growth in 2023, generating $37.2 billion in ...

Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor ...

Predators and prey in the ocean rely on chemical signals for survival, but this vital sensory mode can also be their Achilles ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an ...

在动荡的市场环境中，市值15.5亿美元的Structure Therapeutics ADR (GPCR)股价已触及52周低点，跌至25.89美元。根据 InvestingPro ...

The TouCAHn trial is an open-label, global, Phase 2 study designed to evaluate the efficacy, safety, and pharmacokinetics of ...

该研究首次发现并命名了一种肠道激素——Cholesin（肠抑脂素），并揭示了Cholesin调控机体 胆固醇 ...

Fintel reports that on January 8, 2025, Stifel initiated coverage of Structure Therapeutics Inc. - Depositary Receipt () ...

Suven Life Sciences surged 9.51% to Rs 138.70 after the firm dosed first subjects in a Phase-1 clinical trial of SUVN-I6107 being conducted in USA under FDA acceptance of investigational new drug (IND ...

Structure Therapeutics, Inc. Sponsored ADR (GPCR) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Annabel Samimy.Stay ...

Septerna, Inc., a clinical-stage biotech company specializing in G protein-coupled receptor (GPCR) drug discovery, announced the appointment of Gil M. Labrucherie as the Chief Financial Officer, ...

G protein-coupled receptors (GPCRs), crucial for diverse physiological responses, have traditionally been investigated in ...